摘要
目的探讨卡培他滨与多西他赛联合治疗激素抵抗性晚期前列腺癌的临床疗效。方法回顾性分析2008年1月～2011年10月收治的13例激素抵抗性晚期前列腺癌患者,给予卡培他滨与多西他赛方案化疗。比较化疗前后血清总前列腺特异性抗原(PSA)、疼痛缓解及不良反应发生情况。结果 13例均接受治疗2～5个周期,平均周期为3.2个。达到PSA有效者9例(9/13,69.2%),稳定者3例(3/13,23.1%),无效者1例(1/13,7.7%)。化疗前NRS评分平均分数为4.94分。化疗后NRS平均分数为2.58分。疼痛缓解平均时间为8.4d。Karnofsky评分治疗前60分、70分、80分、90分,分别为1例、4例、5例、3例,治疗后60分、70分、80分、90分,分别为0例、3例、5例、5例。本组不良反应主要表现为不同程度的白细胞减少、血小板减少、肌肉关节痛、恶心呕吐以及转氨酶升高。未出现严重肝肾毒性反应。结论卡培他滨与多西他赛化疗方案治疗激素抵抗性晚期前列腺癌,临床疗效确切,且无严重的毒副反应,可以耐受。
Objective To evaluate the effect of combine capecitabine and Docetaxel to prostatic carcinoma. Methods Analysis of our hospital from January 2008 to October 2011 were treated prostatic carcinoma （13 cases）,all cases were given capecitabine and Docetaxel. Contrast the prostate specific antigen （PSA）, relieve of ache, adverse effect in the pre-therapy and post-therapy. Results All cases were given the 2-5 periodicity（average 3.2）.The effective of SPA were 9 cases （9/13,69.2%）,stable 3 cases（3/13,23.1%）,uneffective 1 case（ 1/13,7.7%）.The grades of NRS were 4.94 and 2.58 in the chems pre-therapy and post-therapy. The average time of relieve of ache 8.4 days. The grades of Karnofsky were 60 scores,70 scores,80 scores,90 scores,and 1 case,4 cases.5 cases.3 cases in the pre-therapy,and 60 scores,70 scores,80 scores,90 scores,and 0 case,3 cases,5 cases, 5 cases in the post-therapy. There were no serious adverse effects, including aleucocytosis, plate-reduction, muscle and joint ache, hyper-aminopherase. Conclusion It is effective of capecitabine and Docetaxel to prostatic carcinoma, and it has no serious adverse effects.
出处
《当代医学》
2012年第32期135-136,共2页
Contemporary Medicine
关键词
前列腺癌
卡培他滨
多西他赛
疗效
Prostatic carcinoma
Capecitabine
Docetaxel
Therapeutic effect
